BONESUPPORT HOLDING AB (publ), a leading company in orthobiologics for the management of bone injuries, will publish its Interim Report Q2 2022, on the 14 July 2022 at 08.00 am CEST.
The Company will hold a conference call and an online presentation on the same day at 10.00 am CEST. The call will be hosted by Emil Billbäck, CEO and Håkan Johansson, CFO who will present the results and answer questions. The presentation will be held in English.
The dial-in numbers for the conference call are:
SE: +46 8 50516386
UK: +44 2031984884
US: +1 4123176300
N.B. use this pin code for all participant numbers: 9287918#
The presentation will be webcasted and can be accessed from the following weblink:
For more information contact:
BONESUPPORT Holding AB
Emil Billbäck, CEO
+46 (0) 46 286 53 70
+46 (0) 708 76 87 87
BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. The company is conducting several clinical studies to further demonstrate the clinical and health economic benefits its products deliver. The company is based in Lund, Sweden, and the net sales amounted to SEK 213 million in 2021. Please visit www.bonesupport.com for more information.
BONESUPPORT and CERAMENT are registered trademarks of BONESUPPORT AB.